Partnering

ResQ Biotech welcomes collaborations from early discovery through preclinical development. The platform is uniquely positioned to tackle challenging protein targets across the protein misfolding landscape, partnering with companies committed to bringing transformative therapies to patients.

Two ways to partner

Co-development & licensing

ResQ Biotech co-develops and out-licenses lead programs against high-priority targets in its internal portfolio:

  • Tauopathies — Alzheimer's disease, progressive supranuclear palsy (PSP), and related tauopathies (lead candidate: RSQ-020).
  • ALS — SOD1-linked and mechanistically related forms.

Engagements range from co-development of advanced lead molecules to licensing of preclinical assets.

Discovery as a service

ResQ Biotech applies its platform to discover therapeutic candidates against partner-priority targets — across any protein misfolding disease. The CycloFINDER™ engine identifies functionally validated hits in living cells, typically in weeks rather than months, with composition-of-matter IP arising from the engagement.

Get in touch

Partnership inquiries: partnering@resqbiotech.com

Reach out.

Get in touchLearn more